Contact this trialFirst, we need to learn more about you.
PD-L1 Inhibitor
Avelumab +1 More for Head and Neck Squamous Cell Carcinoma
Recruiting1 awardPhase 1
New York, New York
This trial is testing the safety of a new treatment called oncolytic adenovirus TILT-123, along with a drug called avelumab, in patients with advanced solid tumors that have
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.